Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26.3M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
400
-
Shares change
-
0
-
Total reported value, excl. options
-
$1K
-
Value change
-
$0
-
Price
-
$2.04
Significant Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q4 2023
4 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q4 2023.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 400 shares
of 26.3M outstanding shares and own 0% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (24.8K shares), CITADEL ADVISORS LLC (21.6K shares), TSFG, LLC (400 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (21.7K shares), Redmile Group, LLC (2.07M shares), Novo Holdings A/S (1.88M shares), TANG CAPITAL MANAGEMENT LLC (841K shares), Bruce & Co., Inc. (772K shares), Alpha Wave Global, LP (108K shares), and PNC FINANCIAL SERVICES GROUP, INC. (65K shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.